ObjectiveTo observe the effect of warm needle moxibustion and exercise therapy on scapulohumeral periarthrits.Methods90 scapulohumeral periarthrits cases were randomly divided into the synthetic treatment group and exercise therapy group with 45 cases in each group. Patients of the synthetic treatment group were treated with warm needle moxibustion and exercise therapy, but that of the exercise therapy group only with exercise therapy. Some local acupoints, for example Point LI15 (Jian Yu), Piont SJ14 (Jian Liao), Piont SI9 (Jian Zhen) and so on, were selected when warm needle moxibustion performed. Eexercise therapy includes joint mobilization and initiative function training. One course was 15 days. The effect was evaluated after two courses.ResultsApparent efficiency of synthetic treatment groups was 71% and 42% for exercise therapy groups. There was a significant difference between two groups (χ2=22.815,P<0.01). There was also a obvious difference between two groups in improving range of shoulder joint movement and alleviating extent of shoulder pain (P<0.05).ConclusionWarm needle moxibustion cooperated with exercise therapy can increase cure rate and reduce recrudescence of scapulohumeral periarthrits.

BACKGROUND: Coronary artery disease (CAD) is the commonest cause of heart failure (HF), whereas pulmonary hypertension (PH) has not been established or reported in this patient population. Therefore, we assessed the prevalence, risk factors, and survival in CAD-associated HF (CAD-HF) complicated with PH. METHODS: Symptomatic CAD-HF patients were continuously enrolled in this prospective, multicenter registry study. Echocardiography, coronary arteriography, left and right heart catheterization (RHC), and other baseline clinical data were recorded. Patients were followed up and their survival was recorded. RESULTS: One hundred and eighty-two CAD-HF patients were enrolled, including 142 with HF with a preserved ejection fraction (heart failure with preserved ejection fraction [HFpEF]; left ventricular ejection fraction [LVEF] ≥50%) and 40 with a reduced ejection fraction (heart failure with reduced ejection fraction [HFrEF]; LVEF < 50%). PH was diagnosed with RHC in 77.5% of patients. Patients with PH showed worse hemodynamic parameters and higher mortality. HFrEF-PH patients had worse survival than HFpEF-PH patients. CAD-HF patients with an enlarged left ventricular end-diastolic diameter and reduced hemoglobin were at higher risk of PH. Nitrate treatment reduced the risk of PH. Elevated creatinine and mean pulmonary arterial pressure (mPAP), diastolic pressure gradient (DPG) ≥7 mmHg, and previous myocardial infarction (MI) entailed a higher risk of mortality in CAD-HF patients with PH. CONCLUSIONS: PH is common in CAD-HF and worsens the hemodynamics and survival in these patients. Left ventricle enlargement and anemia increase the risk of PH in CAD-HF. Patients may benefit from nitrate medications. Renal impairment, elevated mPAP, DPG ≥7 mmHg, and previous MI are strong predictors of mortality in CAD-HF-PH patients. TRIAL REGISTRATION ClinicalTrials.gov, NCT02164526.
Coronary Artery Disease/epidemiology* ; Creatinine ; Heart Failure/complications* ; Humans ; Hypertension, Pulmonary/complications* ; Nitrates ; Prevalence ; Prognosis ; Prospective Studies ; Registries ; Risk Factors ; Stroke Volume ; Ventricular Function, Left